260 likes | 374 Views
HER2 Immunohistochemistry: Workflow Experience with Image Analysis Based Interpretation of CB11 and 4B5 Clones. Jeffrey Fine MD, Rohit Bhargava MD, Urvashi Surthi PhD, and David Dabbs MD Magee-Womens Hospital of UPMC. Disclaimer.
E N D
HER2 Immunohistochemistry: Workflow Experience with Image Analysis Based Interpretation of CB11 and 4B5 Clones Jeffrey Fine MD, Rohit Bhargava MD, Urvashi Surthi PhD, and David Dabbs MD Magee-Womens Hospital of UPMC
Disclaimer • One of the abstract authors (David Dabbs) is a consultant for Ventana • None of the other authors have any conflicts of interest to report
Objectives • Overview of Her2/NEU testing (IHC) • Recap of validation results • Discuss implementation of image analysis
Her2/NEU • Test for responsiveness to Trastuzumab (Herceptin) • Trastuzumab is cardiotoxic and is very expensive • False positives are highly undesirable • Trastuzumab can increase survival or reduce risk of recurrence • False negatives are also undesirable
CAP HER2-A Survey (Spring 2007) • 40 TMA cores (4 slides) • Stained/interpreted at institutions (350ish) • Consensus (>80%) in 22 of 40 cases • Very variable
IHC Variables • Pre-analytic • Fixation issues, tissue processing • Analytic • Validation, Calibration, Antibody clone, Antigen retrieval, Automation, Controls, etc. • Post-analytic • Interpretation criteria • QA procedures • Image analysis (17.9% reported using it)
Validation of IA at UPMC • Formalin fixed (8-48 hours) paraffin embedded tissue • Automated IHC platform (Ventana) • CB11 and 4B5 antibodies (Ventana) • VIAS (Ventana Image Analysis System) • FISH (Vysis)
Validation Results I • System differentiated between tumor and stroma (subjective impression) • Pathologist had to find invasive tumor (and exclude in-situ tumor)
Results CB11 • 100% Concordance with FISH (n=52) • 0/1+ IHC with no amp by FISH • 3+ with amp by FISH • FISH rate (2+ rate): • Expert 22.9% (n=118) • VIAS 21.2% • (expert was also 100% concordant)
Results 4B5 • 94.6% Concordance with FISH (n=56) • 100% Concordance with new reference range • FISH rate (2+): • Expert 21.9% (n=114) • VIAS 28.9% (n=117) • *new reference range
Reference Range • VIAS assigns a raw number score to each case which is then rounded to the nearest whole number. • Out of the box—score 2.5 or higher was rounded to “3+” • New range is conservative—only cases with score 3.5 are called “3+”
Office Mailbox Old Workflow Order Her2/NEU Retrieve IHC Stain Interpret Stain Dictate Results Sign out case
IA Workstation Office Mailbox New Workflow Order Her2/NEU Retrieve IHC Stain Perform IA Dictate Results Sign out case
Implementation Details • Billing • Fee code 88361 • Technical charge initiated by order in APLIS • Documentation • VIAS results printout retained with other case paperwork (requisition) • IHC results (ER/PR and Her2/NEU) dictated into canned text that includes VIAS blurb
Documentation Support • Transcription • New “quick text” with VIAS sentence • Communication with Transcription Team • Slide/paper management personnel • Communication – do not discard results report • Back-up of data • Currently performed manually
IA charged per “click” IHC Laboratory responsible for keeping an adequate supply of the click reagent Smart Card (100 tests) “Consumables” Image from nist.gov www site
Training • Local Domain Expert (me) • Fellows • Selected Faculty • Other Faculty • Residents
Status Report • IA is in production for a week • Bumps being ironed out • Transcription • Training • End experience varies
Good • Should increase standardization • Recent switch to 4B5 clone – different appearance and possible differences in interpretation • Documented response to pressure for accurate Her2/NEU testing • Foot in the door for other IA applications • Vendor has been responsive and appears to want to improve shortcomings
Bad • IA of new antibody is less accurate than that of discontinued antibody • Reference range work-around • Workflow involves “travel” and is more labor intensive than traditional method • Quality improvement but does not extend the pathologist • Operator error is possible • Data entry • Lighting • Focusing
Future IA (More Automation) • Whole Slide Images (some systems do permit IA) • Slide could be scanned in the IHC lab, and results (with the electronic slide) delivered straight to the pathologist • Automated detection of invasive tumor • Transition of IA to non-pathologist staff • Electronic interfaces to support test ordering and resulting (no more paper print outs or dictation)
Conclusions • IA is validated and should improve performance of Her2/NEU IHC testing by reducing post-analytic variability • Current IA set-up not ideal but an important first step: • Successful implementation in a busy academic setting • Revenue (digital pathology business case)